Facts and Figures: 2.590 Forscher*innenprofile (davon 1582 mit ORCID-ID), 8.715 Forschungsprojekte, 154.073 Publikationen, Posters und Vorträge, 64.010 Volltextlinks (davon Volltext frei zugänglich: > 28.094 (Open Access) )
Aktuelle Zitierungen im Web of Science: 1.969.110, davon 3.871 citation classics (>=100 Zitierungen) Summe Altmetrics Score: 297.168
HER2-gerichteter M13-Bakteriophage als Träger für TRAIL zur gezielten Therapie von Brustkrebs
Projektleitung: Eigenfeld Marco
Laufzeit: 01.10.2025 - 30.09.2027
Geldgeber: Österreichische Agentur für internationale Mobilität und Kooperation in Bildung, Wissenschaft und Forschung, OeAD GmbH (ÖAD)
Auf dem Weg zu einem umfassenden Atlas des menschlichen Atmungsmikrobioms: Taxonomische, genomische und funktionelle Perspektiven
Projektleitung: Moissl-Eichinger Christine
Laufzeit: 01.08.2025 - 31.07.2026
Geldgeber: MEFOgraz
Klötzer, KA; Abedini, A; Li, S; Balzer, MS; Liang, X; Levinsohn, J; Ha, E; Dumoulin, B; Hogan, JJ; Quinn, G; Bloom, RD; Schuller, M; Eller, K; Halmos, B; Zhang, NR; Susztak, K
Analysis of individual patient pathway coordination in a cross-species single-cell kidney atlas.
Nat Genet. 2025;
Doi: 10.1038/s41588-025-02285-0
PubMed
FullText
FullText_MUG
08.08.2025:
Saxena, M; Laffin, L; Borghi, C; Fernandez, Fernandez, B; Ghali, JK; Kopjar, B; Polu, K; Roger, SD; Slingsby, BT; Strutz, F; Vogt, L; Weir, MR; Rodman, D, , Launch-HTN, Investigators
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.
JAMA. 2025; 334(5):409-418
Doi: 10.1001/jama.2025.9413
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
08.08.2025:
Masi, S; Dalpiaz, H; Piludu, S; Piani, F; Fiorini, G; Borghi, C
New strategies for the treatment of hyperkalemia.
Eur J Intern Med. 2025; 132:18-26
Doi: 10.1016/j.ejim.2024.10.016
PubMed
FullText
FullText_MUG
04.08.2025:
Vladi, N; Englisch, C; Berger, JM; Moik, F; Berghoff, AS; Preusser, M; Pabinger, I; Ay, C
Validation of risk assessment models for venous thromboembolism in patients with cancer receiving systemic therapies
BLOOD ADV. 2025; 9(13): 3340-3349.
Doi: 10.1182/bloodadvances.2025016044
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Med Uni Graz publications1 were assigned quintiles according to the normalized2 Clarivate’s Journal Impact Factor of the journal at the time of publication.
Proportional Distribution: The color-coded columns show the distribution by JIFnorm-quintiles, while the left vertical axis indicates the proportion relative to the total articles published in a given year. The red line shows the total number of articles published each year (right vertical axis).
Absolute Impact: The sum of the normalized JIFs for all published articles in a given year, color-coded according to the respective quintile.
1 This analysis considered only publications categorized as full papers/original articles.
2 IFnorm = (number of journals in WoS category - ranking of journal + 1) / number of journals in JCR SCIE/SSCI category. An IFnorm of 0.8 means that 20% of the journals in this subject category have a higher IF than the respective journal. The highest possible IFnorm is 1, which means that this journal currently has the highest IF in this subject category.